Cheraw Chronicle

Complete News World

KU Leuven subsidiary raises 30 million euros for vaccine development |  Sciences

KU Leuven subsidiary raises 30 million euros for vaccine development | Sciences

Astrivax, a subsidiary of KU Leuven, has raised €30 million from investors to develop its vaccine platform. Co-founder virologist Johann Nets has been working on a candidate yellow fever vaccine for some time, but is also aiming for rabies vaccines and one for chronic hepatitis B, apparently.

This is the largest start-up capital ever raised for the Leuven subsidiary. Astrivax wants to develop new vaccines that are easier to produce and have lower cold chain requirements during transportation. New vaccines should provide “comprehensive, long-term protection against a variety of viruses and other pathogens.” CEO Hanne Calewaert, one of the other founders, is using the University of Leuven’s Rega Institute for this purpose.

The company will use the new funds for the clinical development phase of a “thermable” yellow fever vaccine and for the development of vaccine candidates to prevent rabies and to treat chronic hepatitis B on the other. Work is also continuing on a vaccine platform that can be used to develop all types of vaccines to prevent and treat infectious diseases.

The two main investors are V-Bio Ventures and Fund +. Also in the capital round were Flanders Future TechFund, Thuja Capital, Ackermans & van Haaren, Mérieux Equity Partners, BNP Paribas Fortis Private Equity and Gemma Frisius Fund of KU Leuven.